MICHAEL KURTZ: Open Payments
NPI 1194814020 · GARDEN GROVE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,592 in 70 payments from 22 companies in 2025. Trend: 2023 $2,140 · 2024 $1,766 · 2025 $1,592
Food & beverage: $1,592
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 8 | $289 |
| AstraZeneca Pharmaceuticals LP | 10 | $231 |
| ABBVIE INC. | 9 | $222 |
| Novo Nordisk Inc | 8 | $141 |
| Antares Pharma, Inc. | 6 | $116 |
| Bausch Health US, LLC | 5 | $107 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $106 |
| Amgen Inc. | 3 | $52 |
| Verity Pharmaceuticals Inc. | 1 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
Products named: SPRAVATO, XYOSTED, Ozempic, APLENZIN, FARXIGA, QULIPTA, XIFAXAN, AIRSUPRA.
Industry payments across CA — which companies pay providers there.
